title: Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?
abstract: IgA nephropathy (IgAN) is characterized by a variable clinical course and multifaceted pathophysiology. There is substantial evidence to suggest that complement activation plays a pivotal role in the pathogenesis of the disease. Therefore, complement inhibition using the humanized anti-C5 monoclonal antibody eculizumab could be a rational treatment. We report here a 16-year-old male with the vasculitic form of IgAN who failed to respond to aggressive conventional therapy including high-dose steroids, cyclophosphamide and plasma exchange and who was treated with four weekly doses of 900 mg eculizumab followed by a single dose of 1200 mg. He responded rapidly to this treatment and has had a stable creatinine around 150 µmol/L (1.67 mg/dL) for >6 months. However, proteinuria was unabated on maximal conventional anti-proteinuric treatment, and a repeat renal biopsy 11 months after presentation revealed severe chronic changes. We believe this case provides proof of principle that complement inhibition may be beneficial in IgAN but also that development of chronicity may be independent of complement.
authors.affiliation: Department of Nephrology , Aalborg University Hospital , Aalborg , Denmark.
authors.forename: Troels
authors.initials: T
authors.lastname: Ring
authors.affiliation: Department of Nephrology , Aalborg University Hospital , Aalborg , Denmark.
authors.forename: Birgitte Bang
authors.initials: BB
authors.lastname: Pedersen
authors.affiliation: Department of Pathology , Aalborg University Hospital , Aalborg , Denmark.
authors.forename: Giedrius
authors.initials: G
authors.lastname: Salkus
authors.affiliation: Institute of Genetic Medicine , Newcastle University , Newcastle upon Tyne , UK.
authors.forename: Timothy H J
authors.initials: TH
authors.lastname: Goodship
keywords: IgA nephritis; complement; eculizumab; fibrosis